UNC Lineberger faculty headline AACR RAS conference

The oncogene RAS is linked to 30 percent of human cancers, but the search for a targeted therapy for RAS has remained elusive. Three leading RAS researchers from the University of North Carolina Lineberger Comprehensive Cancer Center are playing leading roles at a conference aimed at discussing recent advances that may lead to new advances in targeting the oncogene.

As recent research has revealed a greater understanding of the biology of RAS, the National Cancer Institute has announced a megaproject to support efforts to translate these findings into clinically useful drugs.  The American Association for Cancer Research’s RAS Oncogenes: From Biology to Therapy conference from Feb. 24-17 in Lake Buena Vista, Fla. will bring together RAS researchers from across the world to share their discoveries and plan the next steps in targeting the elusive oncogene.

Channing Der, PhD, Sarah Graham Kenan Professor of Pharmacology and UNC Lineberger member, is one of the organizers of the conference. Dr. Der will lead a plenary session and present a lecture on “Prolonged ERK inhibition causes a Myc degradation associated senescence-like growth suppression of KRAS mutant pancreatic cancer.”

Adrienne Cox, PhD, associate professor in the departments of Pharmacology and Radiation Oncology and a UNC Lineberger member, will chair a session on the basic biology of RAS and present on “From RAS to ERK: Unraveling the importance of isoform differences.”

Sharon Campbell, PhD, professor of Biochemistry and Biophysics and UNC Lineberger member, will deliver a talk on “Activation of RAS by post-translational modification: Ubiquitination and thiol oxidation.”

For more information, visit the conference website.Icon indicating that a link will open an external site.